Paper Details

  1. Home
  2. Paper Details

New drugs approved for acute myeloid leukaemia in 2018.

Author: EskazanAhmet Emre, KucukyurtSelin

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

New targeted therapy agents, such as glasdegib, venetoclax, ivosidenib, and gilteritinib, have been approved by the US Food and Drug Administration for the treatment of AML.
Paper Details　
Original Abstract of the Article :
Acute myeloid leukaemia (AML) is a haematopoietic stem cell disorder, that is characterized by the clonal expansion of myeloid blasts and suppression of normal haematopoiesis. The 3 + 7 regimen is the backbone of standard first-line induction therapy among young/fit patients. However, in elderly and...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955409/

データ提供：米国国立医学図書館（NLM）

New Drugs Approved for Acute Myeloid Leukemia: A 2018 Update

This review provides an overview of the new drugs approved by the US Food and Drug Administration (FDA) in 2018 for the treatment of acute myeloid leukemia (AML). The authors highlight four targeted therapy agents, glasdegib, venetoclax, ivosidenib, and gilteritinib, and discuss their potential roles in treating AML patients with different risk profiles and treatment histories.

Targeted Therapy Agents: A New Era in AML Treatment

The review highlights the development of targeted therapy agents for AML, representing a significant advance in treating this challenging disease. These agents offer new treatment options for patients with high-risk AML, relapsed/refractory AML, and those who cannot tolerate traditional intensive chemotherapy regimens.

AML Treatment: A Journey Through the Desert of Complexity

This review provides a comprehensive overview of the evolving landscape of AML treatment. It's like navigating a vast desert, where each new discovery offers a potential oasis, providing a fresh perspective and new solutions for combating this complex disease. The development of targeted therapy agents represents a significant step forward in the fight against AML, offering hope for improved outcomes for patients.

Dr.Camel's Conclusion

This review showcases the remarkable progress in AML treatment, with the advent of targeted therapy agents offering new hope for patients. These agents provide a more tailored approach to treatment, targeting specific molecular pathways and offering potential benefits for those with high-risk or refractory AML. It's a testament to the tireless efforts of researchers to find effective solutions for this challenging disease. As we continue our journey through the desert of medical research, we can anticipate further breakthroughs in the fight against AML, leading to improved treatments and better outcomes for patients.
Date :
  1. Date Completed 2020-09-28
  2. Date Revised 2021-01-10
Further Info :

Pubmed ID

31469910

DOI: Digital Object Identifier

PMC6955409

Related Literature

Article Analysis
・Effects of glasdegib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.